Role of AMP-activated Protein Kinase and Adiponectin during Development of Hepatic Steatosis in High-fat Diet-induced Obesity in Rats

Journal of Comparative Pathology

Volumn 145, Issue 1, 2011, Pages 88-94

  Ha, S K ^a   Kim, J ^b   Chae, C ^a  

^a Seoul National University   (South Korea)

^b Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Adipokine; Fatty liver; High fat diet; Obesity; Rat

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA ACTIN; CHOLESTEROL; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BROWN ADIPOSE TISSUE; CELL VACUOLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EPIDIDYMIS FAT; FATTY ACID BLOOD LEVEL; FATTY LIVER; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; LIPID DIET; LIPID LIVER LEVEL; LIPID METABOLISM; LIVER CELL; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ADIPONECTIN; ANIMALS; DIET; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY LIVER; LIVER; MALE; OBESITY; PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS;

EID: 79955993481     PISSN: 00219975     EISSN: 15323129     Source Type: Journal    
DOI: 10.1016/j.jcpa.2010.11.011     Document Type: Article

References (35)

1. Adams L.A., Angulo P., Lindor K.D. Nonalcoholic fatty liver disease. Canadian Medical Association Journal 2005, 172:899-905.
2. Ahren B., Scheurink A.J. Marked hyperleptinemia after high-fat diet associated with severe glucose intolerance in mice. European Journal of Endocrinology 1998, 139:461-467.
3. Anstee Q.M., Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. International Journal of Experimental Pathology 2006, 87:1-16.
4. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications 1999, 257:79-83.
5. Banno R., Arima H., Hayashi M., Goto M., Watanabe M., et al. Central administration of melanocortin agonist increased insulin sensitivity in diet-induced obese rats. FEBS Letters 2007, 581:1131-1136.
6. Bradbury M.W. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. American Journal of Physiology: Gastrointestinal and Liver Physiology 2006, 290:G194-G198.
7. Chen S., Chen Y., Shi J., Lin Y., Xie W. The restorative effect of taurine on experimental nonalcoholic steatohepatitis. Digestive Diseases and Sciences 2006, 51:2225-2234.
8. Fujimoto M., Shimizu N., Kunii K., Martyn J.A., Ueki K., et al. A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes 2005, 54:1340-1348.
9. Ghibaudi L., Cook J., Farley C., van Heek M., Hwa J.J. Fat intake affects adiposity, comorbidity factors, and energy metabolism of sprague-dawley rats. Obesity Research 2002, 10:956-963.
10. Guo X.R., Gong H.X., Gao Y.Q., Fei L., Ni Y.H., et al. A mutation in signal peptide of rat resistin gene inhibits differentiation of 3T3-L1 preadipocytes. Acta Pharmacologica Sinica 2004, 25:1705-1711.
11. James P.T., Leach R., Kalamara E., Shayeghi M. The worldwide obesity epidemic. Obesity Research 2001, 9(Suppl. 4):228S-233S.
12. Ji H., Friedman M.I. Reduced capacity for fatty acid oxidation in rats with inherited susceptibility to diet-induced obesity. Metabolism: Clinical and Experimental 2007, 56:1124-1130.
13. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. Journal of Clinical Investigation 2006, 116:1784-1792.
14. Kasim-Karakas S.E., Tsodikov A., Singh U., Jialal I. Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. American Journal of Clinical Nutrition 2006, 83:774-779.
15. Li S., Zhang H.Y., Hu C.C., Lawrence F., Gallagher K.E., et al. Assessment of diet-induced obese rats as an obesity model by comparative functional genomics. Obesity 2008, 16:811-818.
16. Long Y.C., Zierath J.R. AMP-activated protein kinase signaling in metabolic regulation. Journal of Clinical Investigation 2006, 116:1776-1783.
17. Matteoni C., Younossi Z., Gramlich T., Boparai N., Liu Y., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
18. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Journal of the American Medical Association 2003, 289:76-79.
19. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Progress in Lipid Research 2009, 48:1-26.
20. Nouchi T., Worner T.M., Sato S., Lieber C.S. Serum procollagen type III N-terminal peptides and laminin P1 peptide in alcoholic liver disease. Alcoholism, Clinical and Experimental Research 1987, 11:287-291.
21. Pi-Sunyer F.X. The relation of adipose tissue to cardiometabolic risk. Clinical Cornerstone 2006, 8(Suppl. 4):S14-S23.
22. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., et al. Plasma adiponectin levels and risk of myocardial infarction in men. Journal of the American Medical Association 2004, 291:1730-1737.
23. Rogers C.Q., Ajmo J.M., You M. Adiponectin and alcoholic fatty liver disease. IUBMB Life 2008, 60:790-797.
24. Rossmeisl M., Rim J.S., Koza R.A., Kozak L.P. Variation in type 2 diabetes-related traits in mouse strains susceptible to diet-induced obesity. Diabetes 2003, 52:1958-1966.
25. Sardesai V.M., Manning J.A. The determination of triglycerides in plasma and tissues. Clinical Chemistry 1968, 14:156-161.
26. Sekiya N., Shibahara N., Sakakibara I., Hattori N., Goto H., et al. Inhibitory effects of Oren-Gedoku-To (Huanglian-Jie-Du-Tang) on free radical-induced lysis of human red blood cells. Phytotherapy Research 2003, 17:147-151.
27. Shimada M., Mochizuki K., Sakurai N., Goda T. Dietary supplementation with epigallocatechin gallate elevates levels of circulating adiponectin in non-obese type-2 diabetic Goto-Kakizaki rats. Bioscience, Biotechnology and Biochemistry 2007, 71:2079-2082.
28. Smith B.K., Andrews P.K., West D.B. Macronutrient diet selection in thirteen mouse strains. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 2000, 278:R797-R805.
29. Svegliati-Baroni G., Candelaresi C., Saccomanno S., Ferretti G., Bachetti T., et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. American Journal of Pathology 2006, 169:846-860.
30. Terra X., Pallarés V., Ardèvol A., Bladé C., Fernández-Larrea J., et al. Modulatory effect of grape-seed procyanidins on local and systemic inflammation in diet-induced obesity rats. Journal of Nutritional Biochemistry 2010, doi:10.1016/j.jnutbio.2010.03.006.
31. Tschop M., Heiman M.L. Rodent obesity models: an overview. Experimental and Clinical Endocrinology & Diabetes 2001, 109:307-319.
32. Waki H., Yamauchi T., Kamon J., Ito Y., Uchida S., et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. Journal of Biological Chemistry 2003, 278:40352-40363.
33. West D.B., Boozer C.N., Moody D.L., Atkinson R.L. Dietary obesity in nine inbred mouse strains. American Journal of Physiology 1992, 262:R1025-R1032.
34. Winder W.W., Hardie D.G. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. American Journal of Physiology 1999, 277:E1-E10.
35. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. Journal of Clinical Investigation 2003, 112:91-100.